Insight

Intratumoral immune triads are required for effective immunotherapy

Photo taken from NCI/LinkedIn

Jun 26, 2024, 02:10

Intratumoral immune triads are required for effective immunotherapy

NCI Division of Cancer Biology shared on X:

“Using preclinical models in an NCI-funded study, Gabriel Espinosa Carrasco, The SchietiLab, et al. found that intratumoral immune triads (with a dendritic cell, CD4 T cell, and CD8 T cell) are required for effective immunotherapy.”

immunotherapy

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors

Authors: Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D. Hellmann, Bryan M. Burt, Hyun-Sung Lee, Andrea Schietinger

Source: NCI Division of Cancer Biology/X

Andrea Schietinger Asim Dave Aurora Scrivo Bryan M. Burt cancer Doron Betel Edison Chiu Gabriel Espinosa Carrasco Hee-Jin Jang Hyun-Sung Lee immunotherapy Matthew D. Hellmann NCI Division of Cancer Biology OncoDaily Oncology Paul Zumbo Sung Wook Kang The SchietiLab

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage